Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma
Clinical trial NCT04093323 · TERMINATED
Trial details
- NCT number
- NCT04093323
- Sponsor
- Roswell Park Cancer Institute
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-11-13
- Primary completion
- 2025-04-03
- Enrollment
- 1
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.